Comparison of intravenous lidocaine/ketorolac combination to either analgesic alone for suspected renal colic pain in the ED.


Journal

The American journal of emergency medicine
ISSN: 1532-8171
Titre abrégé: Am J Emerg Med
Pays: United States
ID NLM: 8309942

Informations de publication

Date de publication:
02 2020
Historique:
received: 02 01 2019
accepted: 28 01 2019
pubmed: 17 2 2019
medline: 18 6 2020
entrez: 17 2 2019
Statut: ppublish

Résumé

To compare analgesic efficacy and safety of intravenous lidocaine and ketorolac combination to each analgesic alone for ED patients with suspected renal colic. We conducted a randomized, double-blind trial comparing analgesic efficacy of a combination of intravenous lidocaine (1.5 mg/kg) and ketorolac (30 mg), to ketorolac (30 mg), and to lidocaine (1.5 mg/kg) in patients aged 18-64 presenting to the ED with suspected renal colic. Primary outcome included difference in pain scores between the groups at 30 min. Secondary outcomes included a comparative reduction in pain scores in each group from baseline to 30 and 60 min as well as rates of adverse events and need for rescue analgesia at 30 and 60 min. We enrolled 150 subjects (50 per group). The difference in mean pain scores at 30 min between Lidocaine and Lidocaine/Ketorolac groups was -2.89 (95% CI: -4.39 to -1.39); between Ketorolac and Lidocaine/Ketorolac group was -0.92 (95% CI: -2.44 to 0.61); and between Ketorolac and Lidocaine was -1.98 (95% CI: -3.69 to -0.27). A comparative percentage of subjects in each group required rescue analgesia at 30 and 60 min. No clinically concerning changes in vital signs were observed. No serious adverse events occurred in either group. Commonly reported adverse effects were dizziness, nausea, and headache. The administration of intravenous lidocaine/ketorolac combination to ED patients with suspected renal colic results in better analgesia in comparison to lidocaine alone but provides no analgesic advantages over ketorolac alone. Clinicaltrials.gov Registration: NCT02902770.

Identifiants

pubmed: 30770244
pii: S0735-6757(19)30070-1
doi: 10.1016/j.ajem.2019.01.048
pii:
doi:

Substances chimiques

Analgesics 0
Drug Combinations 0
Lidocaine 98PI200987
Ketorolac YZI5105V0L

Banques de données

ClinicalTrials.gov
['NCT02902770']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

165-172

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Sergey Motov (S)

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, NY, USA.

Catsim Fassassi (C)

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, NY, USA.

Jefferson Drapkin (J)

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, NY, USA. Electronic address: jdrapkin@maimonidesmed.org.

Mahlaqa Butt (M)

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, NY, USA.

Rukhsana Hossain (R)

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, NY, USA.

Antonios Likourezos (A)

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, NY, USA.

Ralph Monfort (R)

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, NY, USA.

Jason Brady (J)

Department of Pharmacy, Maimonides Medical Center, Brooklyn, NY, USA.

Nechama Rothberger (N)

Department of Pharmacy, Maimonides Medical Center, Brooklyn, NY, USA.

Stefan S Mann (SS)

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, NY, USA.

Peter Flom (P)

Peter Flom Consulting, New York, USA.

Vishal Gulati (V)

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, NY, USA.

John Marshall (J)

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH